Clinical trialPhase 3Completed
Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus mFolfirinox to Treat Resected Pancreatic Adenocarcinoma
Multicentric Randomized Phase III Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus 5-fluorouracil, Leucovorin, Irinotecan and Oxaliplatin (mFolfirinox) in Patients With Resected Pancreatic Adenocarcinoma
- Outcome
- Finished, no results posted
- Phase
- Phase 3
- Status
- Completed
- Study type
- Interventional
- Start
- 16 April 2012
- Expected end
- 16 July 2021
- Enrollment
- 493 participants
- Sites
- 52
- Primary outcomes
- disease-free survival (DFS)
- Sponsor
- Other
- Results posted
- No
- Last update
- 4 January 2022
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 3
- Builds on itImpact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From t… DOI 10.1200/jco-25-02508↗
- Builds on itFive-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. DOI 10.1001/jamaoncol.2022.3829↗
- Builds on itFOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. DOI 10.1056/nejmoa1809775↗